| Study | Exclusion reasons | Remarks | Reference(s) | ||
|---|---|---|---|---|---|
| PRISM, 2019 | randomized controlled trial | inadequate or absent control group | phase II trial to evaluate whether administering IPI once every 12 weeks (modified), instead of once every 3 weeks (standard), in combination with NIVO, is associated with a favorable toxicity profile. |
Buckley BMC Cancer 2019; 19:1102 10.1186/s12885-019-6273-1 Naveen S. Vasudev JCO 42, 312-323(2024) 10.1200/JCO.23.00236 |
|
| COSMIC-313, 2023 | randomized controlled trial | not relevant exposure |
Choueiri TK N Engl J Med 2023;388:1767-1778 May 2023 10.1056/NEJMoa2212851 Choueiri TK N Engl J Med 2023; 388:1767-1778-. 10.1056/NEJMoa2212851 |
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
